Alder Biopharmaceuticals Inc (ALDR) : New Leaf Venture Partners L.l.c. scooped up 40,148 additional shares in Alder Biopharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 230,954 shares of Alder Biopharmaceuticals Inc which is valued at $7,887,079.Alder Biopharmaceuticals Inc makes up approximately 5.54% of New Leaf Venture Partners L.l.c.’s portfolio.
Other Hedge Funds, Including , Perceptive Advisors boosted its stake in ALDR in the latest quarter, The investment management firm added 25,000 additional shares and now holds a total of 400,000 shares of Alder Biopharmaceuticals Inc which is valued at $13,660,000. Alder Biopharmaceuticals Inc makes up approx 0.89% of Perceptive Advisors’s portfolio.Advisor Group boosted its stake in ALDR in the latest quarter, The investment management firm added 76 additional shares and now holds a total of 182 shares of Alder Biopharmaceuticals Inc which is valued at $5,369.Tiaa Cref Investment Management reduced its stake in ALDR by selling 2,728 shares or 1.9% in the most recent quarter. The Hedge Fund company now holds 141,212 shares of ALDR which is valued at $3,685,633.Blackrock Fund Advisors boosted its stake in ALDR in the latest quarter, The investment management firm added 100,431 additional shares and now holds a total of 1,854,944 shares of Alder Biopharmaceuticals Inc which is valued at $48,414,038. Alder Biopharmaceuticals Inc makes up approx 0.01% of Blackrock Fund Advisors’s portfolio.Neuberger Berman Group reduced its stake in ALDR by selling 5,500 shares or 27.5% in the most recent quarter. The Hedge Fund company now holds 14,500 shares of ALDR which is valued at $345,100.
Alder Biopharmaceuticals Inc closed down -0.55 points or -1.88% at $28.75 with 10,24,464 shares getting traded on Monday. Post opening the session at $29.3, the shares hit an intraday low of $27.3 and an intraday high of $29.3 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Alder Biopharmaceuticals Inc reported $-0.70 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $-0.85.During the same quarter in the previous year, the company posted $-0.62 EPS.
Many Wall Street Analysts have commented on Alder Biopharmaceuticals Inc. Alder Biopharmaceuticals Inc was Initiated by Aegis Capital to “Buy” on Nov 7, 2016. Piper Jaffray Initiated Alder Biopharmaceuticals Inc on Oct 31, 2016 to “Overweight”, Price Target of the shares are set at $47.Alder Biopharmaceuticals Inc was Resumed by Brean Capital to “Buy” on Sep 30, 2016.
Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company discovers develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy as well as speed of onset and durability of therapeutic response. The Company’s pipeline includes ALD403 Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6) and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH) and is being developed for the treatment of Cushing’s disease.